AURIS MEDICAL (EARS)

[Triple9]

Congratulations on your win!

$EARS has catalysts coming in 2017 Q4 and 2018 Q1 and Q4:

Phase 3 AM-111 HEALOS - for Acute inner ear hearing loss. Completion of enrollment announced June 5, 2017. Data due 4Q 2017.

Phase 1 AM-125, an intranasal formulation of betahistine for the treatment of Meniere's disease and other vestibular disorders. Goal is to start Phase 1 in Q4 2017.

Phase 3 AM-101 Keyzilen TACTT3 - for Acute inner ear tinnitus. Enrollment resumption announced January 26, 2017 with top-line data 1Q 2018.

Phase 3 AM-111 ASSENT - for Acute inner ear hearing loss. Data due 2H 2018.

$EARS needs some good data on HEALOS! They are clearly hedging with AM-125 in the same quarter. The good news is they are a penny stock bio with THREE Phase 3 trials underway. High risk, high reward.